NCT00771888

Open-Label Extension of LOCKCYST Trial

Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 88 Years
• Healthy volunteers: Not accepted

Summary

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available. Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

Detailed description

van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008 September;57(9):1338-9.

Conditions

• Polycystic Liver Disease
• Hepatomegaly
• Liver Diseases
• Polycystic Kidney
• Autosomal Dominant

Interventions

Type	Name	Description
DRUG	lanreotide	lanreotide

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-10-01
• Completion: 2009-08-01
• First posted: 2008-10-15
• Last updated: 2008-11-13

Locations

2 sites across 2 countries: Belgium, Netherlands